How Can Psychedelics Become Reimbursed Care?
Floris Wolswijk, MSc
Tuesday 29 June, 2025 8PM CET (7PM BST, 2PM EST, 11AM PST)
Online via Zoom
Add to Calendar
The landscape of mental health treatment is on the brink of a revolution. Groundbreaking research into psychedelics—such as psilocybin, MDMA, and ketamine—has shown remarkable outcomes in the treatment of conditions like long-standing depression and post-traumatic stress disorder (PTSD). In many cases, just a few sessions of psychedelic-assisted therapy have led to profound, lasting changes in patients’ mental well-being, where traditional methods have often fallen short.
Yet with all this promise comes a critical question: How do we bring these innovations into mainstream healthcare?
Healthcare systems around the world, including in the Netherlands, are already stretched thin. Providers are overburdened, burnout is rampant, and structural innovation is slow to take root. So, how can we responsibly and effectively integrate psychedelic-assisted therapy into a system that is already struggling to meet existing demands?
In this insightful session, Floris Wolswijk, founder of Blossom, will share key insights from a six-month investigative study into this very challenge. His research focuses on the Dutch healthcare system but draws conclusions and strategies that resonate far beyond national borders.
Floris will explore:
- The current evidence behind psychedelic therapies and their clinical potential
- The barriers to adoption within existing healthcare structures
- Models for responsible, ethical, and scalable integration
- The roles of therapists, institutions, regulators, and patients in this emerging field
- What steps need to be taken now to prepare for a future where psychedelics are part of mainstream care